secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cronos Group Inc. (CRON)
CIK:        0001656472
Form:       8-K
Filed at:   2021-08-06T23:59:59+00:00
Accession:  0001656472-21-000090
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cronos Group Q2 net revenue $15.6M (+58% YoY); gross loss expands to $15.8M; invests $110M in PharmaCann
--------------------------------------------------------------------------------

- Net revenue $15.6M, up 58% YoY; ROW segment $13.4M (+74%) driven by Canada adult-use and Israel medical.
- Gross loss $15.8M (from $2.9M loss); inventory write-downs $12M; Adj EBITDA loss $49.8M.
- Strategic investment: option to acquire ~10.5% stake in PharmaCann for ~$110.4M, with commercial agreements.
- Amended Ginkgo Bioworks agreement; commenced commercial-scale CBG production in June 2021.
- Appointed Kendrick Ashton Jr. to Board; new Head of Regulatory, Global Head of Audit, VP Controller.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1656472/000165647221000090/0001656472-21-000090-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1656472/000165647221000090/cron-20210806.htm
  HTML page:      https://secwatch.observer/filing/0001656472-21-000090

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer